Skip to main content
Erschienen in: Endocrine 1/2024

12.12.2023 | Original Paper

Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism

verfasst von: Daisuke Watanabe, Satoshi Morimoto, Noriko Morishima, Atsuhiro Ichihara

Erschienen in: Endocrine | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

Aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA) are the most common subtypes of primary aldosteronism (PA), and the PA subtype dictates the treatment options. This study aimed to identify predictors of declined estimated glomerular filtration rate (eGFR) following each treatment in patients with APA and IHA.

Methods

We retrospectively investigated 45 patients with APA who had undergone adrenalectomy (ADX) and 37 patients with IHA who had received treatment with a mineralocorticoid receptor antagonist (MRA) to identify pre-treatment risk factors for eGFR decline during the post-treatment follow-up period.

Results

Patients with APA who underwent ADX exhibited higher eGFR declines than patients with IHA treated with MRA at the 6-month post-treatment evaluation point. A high preoperative plasma aldosterone concentration (PAC) in patients with APA and a high body mass index (BMI) in patients with IHA were identified as independent predictors of higher eGFR decline at 6 months post-treatment (β=0.42 and β=0.36, respectively). In patients with APA, the cutoff PAC to best predict a 20% decrease in eGFR following ADX, as determined by receiver operating characteristic analysis, was 524 pg/mL. In patients with IHA, the cutoff BMI to best predict a 10% decrease in eGFR following MRA administration was 25.3 kg/m2. In addition, lower preoperative flow-mediated vasodilation was associated with eGFR decline after ADX in patients with APA.

Conclusions

Greater attention should be given to the above-mentioned risk factors to prevent renal impairment following each treatment in patients with both APA and IHA.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat J.W. Funder, R.M. Carey, F. Mantero et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889–1916 (2016)CrossRefPubMed J.W. Funder, R.M. Carey, F. Mantero et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889–1916 (2016)CrossRefPubMed
2.
Zurück zum Zitat D. Watanabe, S. Morimoto, N. Morishima, A. Ichihara, Clinical impacts of endothelium-dependent flow-mediated vasodilation assessment on primary aldosteronism. Endocr. Connect. 10, 578–587 (2021)CrossRefPubMedPubMedCentral D. Watanabe, S. Morimoto, N. Morishima, A. Ichihara, Clinical impacts of endothelium-dependent flow-mediated vasodilation assessment on primary aldosteronism. Endocr. Connect. 10, 578–587 (2021)CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat M. Choi, U.I. Scholl, P. Yue et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768–772 (2011)CrossRefPubMedPubMedCentral M. Choi, U.I. Scholl, P. Yue et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768–772 (2011)CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat S. Monticone, J. Burrello, D. Tizzani et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 11, 1811–1820 (2017)CrossRef S. Monticone, J. Burrello, D. Tizzani et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 11, 1811–1820 (2017)CrossRef
5.
Zurück zum Zitat M. Yoon, N. Hong, J. Ha et al. Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea. Hypertens. Res. 45, 1418–1429 (2022)CrossRefPubMed M. Yoon, N. Hong, J. Ha et al. Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea. Hypertens. Res. 45, 1418–1429 (2022)CrossRefPubMed
6.
Zurück zum Zitat Y. Takeda, K. Furukawa, S. Inaba, I. Miyamori, H. Mabuchi, Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. J. Clin. Endocrinol. Metab. 84, 1633–1637 (1999)PubMed Y. Takeda, K. Furukawa, S. Inaba, I. Miyamori, H. Mabuchi, Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. J. Clin. Endocrinol. Metab. 84, 1633–1637 (1999)PubMed
7.
Zurück zum Zitat Y. Iwakura, R. Morimoto, M. Kudo et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J. Clin. Endocrinol. Metab. 99, 1593–1598 (2014)CrossRefPubMed Y. Iwakura, R. Morimoto, M. Kudo et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J. Clin. Endocrinol. Metab. 99, 1593–1598 (2014)CrossRefPubMed
8.
Zurück zum Zitat G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72, 658–666 (2018)CrossRefPubMed G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72, 658–666 (2018)CrossRefPubMed
9.
Zurück zum Zitat M. Yoshioka, Y. Nakajima, T. Miyamoto et al. Age-dependent progression of renal dysfunction after adrenalectomy for aldosterone-producing adenomas in Japan. J. Endocr. Soc. 17, 577–589 (2018) M. Yoshioka, Y. Nakajima, T. Miyamoto et al. Age-dependent progression of renal dysfunction after adrenalectomy for aldosterone-producing adenomas in Japan. J. Endocr. Soc. 17, 577–589 (2018)
10.
Zurück zum Zitat H. Kobayashi, M. Abe, Y. Nakamura et al. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function. Hypertension 74, 630–638 (2019)CrossRefPubMed H. Kobayashi, M. Abe, Y. Nakamura et al. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function. Hypertension 74, 630–638 (2019)CrossRefPubMed
11.
Zurück zum Zitat Y. Kobayashi, T. Haze, Y. Yano et al. Associations between changes in plasma renin activity and aldosterone concentrations and changes in kidney function after treatment for primary aldosteronism. Kidney Int. Rep. 20, 1291–1297 (2020)CrossRef Y. Kobayashi, T. Haze, Y. Yano et al. Associations between changes in plasma renin activity and aldosterone concentrations and changes in kidney function after treatment for primary aldosteronism. Kidney Int. Rep. 20, 1291–1297 (2020)CrossRef
12.
Zurück zum Zitat C.K. Chan, W.S. Yang, Y.H. Lin et al. Arterial stiffness is associated with clinical outcome and cardiorenal injury in lateralized primary aldosteronism. J. Clin. Endocrinol. Metab. 105, e3950–e3960 (2020)CrossRef C.K. Chan, W.S. Yang, Y.H. Lin et al. Arterial stiffness is associated with clinical outcome and cardiorenal injury in lateralized primary aldosteronism. J. Clin. Endocrinol. Metab. 105, e3950–e3960 (2020)CrossRef
13.
Zurück zum Zitat T. Nishikawa, M. Omura, F. Satoh et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr. J. 58, 711–721 (2011)CrossRefPubMed T. Nishikawa, M. Omura, F. Satoh et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr. J. 58, 711–721 (2011)CrossRefPubMed
14.
Zurück zum Zitat T.A. Williams, J.W.M. Lenders, P. Mulatero et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 5, 689–699 (2017)CrossRefPubMedPubMedCentral T.A. Williams, J.W.M. Lenders, P. Mulatero et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 5, 689–699 (2017)CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat R. Nakamaru, K. Yamamoto, H. Akasaka et al. Sex differences in renal outcomes after medical treatment for bilateral primary aldosteronism. Hypertension 77, 537–545 (2021)CrossRefPubMed R. Nakamaru, K. Yamamoto, H. Akasaka et al. Sex differences in renal outcomes after medical treatment for bilateral primary aldosteronism. Hypertension 77, 537–545 (2021)CrossRefPubMed
16.
Zurück zum Zitat R. Nakamaru, K. Yamamoto, H. Akasaka et al. Age-stratified comparison of clinical outcomes between medical and surgical treatments in patients with unilateral primary aldosteronism. Sci. Rep. 25, 6925 (2021)CrossRef R. Nakamaru, K. Yamamoto, H. Akasaka et al. Age-stratified comparison of clinical outcomes between medical and surgical treatments in patients with unilateral primary aldosteronism. Sci. Rep. 25, 6925 (2021)CrossRef
17.
Zurück zum Zitat K. Matsushita, J. Coresh, Y. Sang et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 3, 514–525 (2015)CrossRefPubMedPubMedCentral K. Matsushita, J. Coresh, Y. Sang et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 3, 514–525 (2015)CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat X. Lin, M.H.E. Ullah, X. Wu et al. Cerebro-cardiovascular risk, target organ damage, and treatment outcomes in primary aldosteronism. Front. Cardiovasc. Med. 8, 798364 (2022)CrossRefPubMedPubMedCentral X. Lin, M.H.E. Ullah, X. Wu et al. Cerebro-cardiovascular risk, target organ damage, and treatment outcomes in primary aldosteronism. Front. Cardiovasc. Med. 8, 798364 (2022)CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Y. Ohno, M. Sone, N. Inagaki et al. Obesity as a key factor underlying idiopathic hyperaldosteronism. J. Clin. Endocrinol. Metab. 103, 4456–4464 (2018)CrossRefPubMed Y. Ohno, M. Sone, N. Inagaki et al. Obesity as a key factor underlying idiopathic hyperaldosteronism. J. Clin. Endocrinol. Metab. 103, 4456–4464 (2018)CrossRefPubMed
20.
Zurück zum Zitat H. Kataoka, K. Nitta, J. Hoshino, Visceral fat and attribute-based medicine in chronic kidney disease. Front. Endocrinol. (Lausanne) 14, 1097596 (2023)CrossRefPubMed H. Kataoka, K. Nitta, J. Hoshino, Visceral fat and attribute-based medicine in chronic kidney disease. Front. Endocrinol. (Lausanne) 14, 1097596 (2023)CrossRefPubMed
21.
Zurück zum Zitat S. Kishimoto, K. Oki, T. Maruhashi et al. A comparison of adrenalectomy and eplerenone on vascular function in patients with aldosterone-producing adenoma. J. Clin. Endocrinol. Metab. 105, 3474–3485 (2020)CrossRef S. Kishimoto, K. Oki, T. Maruhashi et al. A comparison of adrenalectomy and eplerenone on vascular function in patients with aldosterone-producing adenoma. J. Clin. Endocrinol. Metab. 105, 3474–3485 (2020)CrossRef
22.
Zurück zum Zitat S. Kishimoto, K. Oki, T. Maruhashi et al. KCNJ5 mutation is a predictor for recovery of endothelial function after adrenalectomy in patients with aldosterone-producing adenoma. Hypertens. Res. 46, 2213–2227 (2023)CrossRefPubMed S. Kishimoto, K. Oki, T. Maruhashi et al. KCNJ5 mutation is a predictor for recovery of endothelial function after adrenalectomy in patients with aldosterone-producing adenoma. Hypertens. Res. 46, 2213–2227 (2023)CrossRefPubMed
23.
Zurück zum Zitat M.P. Theodorakopoulou, M. Schoina, P. Sarafidis, Assessment of endothelial and microvascular function in CKD: older and newer techniques, associated risk factors, and relations with outcomes. Am. J. Nephrol. 51, 931–949 (2020)CrossRefPubMed M.P. Theodorakopoulou, M. Schoina, P. Sarafidis, Assessment of endothelial and microvascular function in CKD: older and newer techniques, associated risk factors, and relations with outcomes. Am. J. Nephrol. 51, 931–949 (2020)CrossRefPubMed
24.
Zurück zum Zitat Y. Li, R. Cui, K. Liu et al. Relationship between endothelial dysfunction and prevalence of chronic kidney disease: the circulatory risk in communities study (CIRCS). J. Atheroscler. Thromb. 28, 622–629 (2021)CrossRefPubMed Y. Li, R. Cui, K. Liu et al. Relationship between endothelial dysfunction and prevalence of chronic kidney disease: the circulatory risk in communities study (CIRCS). J. Atheroscler. Thromb. 28, 622–629 (2021)CrossRefPubMed
25.
Zurück zum Zitat C.H. Chang, Y.H. Hu, Y.C. Tsai et al. Arterial stiffness and blood pressure improvement in aldosterone-producing adenoma harboring KCNJ5 mutations after adrenalectomy. Oncotarget 8, 29984–29995 (2017)CrossRefPubMedPubMedCentral C.H. Chang, Y.H. Hu, Y.C. Tsai et al. Arterial stiffness and blood pressure improvement in aldosterone-producing adenoma harboring KCNJ5 mutations after adrenalectomy. Oncotarget 8, 29984–29995 (2017)CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat H. Kobayashi, Y. Nakamura, M. Abe et al. Impact of a change to a novel chemiluminescent immunoassay for measuring plasma aldosterone on the diagnosis of primary aldosteronism. Endocr. J. 70, 489–500 (2023)CrossRefPubMed H. Kobayashi, Y. Nakamura, M. Abe et al. Impact of a change to a novel chemiluminescent immunoassay for measuring plasma aldosterone on the diagnosis of primary aldosteronism. Endocr. J. 70, 489–500 (2023)CrossRefPubMed
Metadaten
Titel
Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism
verfasst von
Daisuke Watanabe
Satoshi Morimoto
Noriko Morishima
Atsuhiro Ichihara
Publikationsdatum
12.12.2023
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03627-w

Weitere Artikel der Ausgabe 1/2024

Endocrine 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.